Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Breast Cancer
Study Phase
Phase 3
Study Completion Date
December 2017
NCT00127205Uploaded 06-04-2021
Access via NCI by Request
PDS UID: nci-data-469
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
Provider Information
Provider Data DescriptionThere are two datasets associated with PMID 31693129: NCT00127205-D1 and NCT00127205-D2. This dataset, NCT00127205-D1, will allow users to reproduce the patient characteristics, treatment completion, and primary outcome results reported in J Natl Cancer Inst. (2020 Jul 1;112(7):698-707. doi: 10.1093/jnci/djz215. PMID: 31693129; PMCID: PMC7357327) for trial NCT00127205.
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryRATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
ConditionsBreast Cancer
Intervention TypeDrug: clodronate disodium
Drug: ibandronate sodium
Drug: zoledronic acid
Drug(s)Drug: zoledronic acid
Drug: clodronate disodium
Drug: ibandronate sodium
Total Enrolled6097
RandomizationRandomized
Blinding MethodNone (Open Label)
Arms InterventionArm I - Experimental
Arm II - Active Comparator
Arm III - Experimental
Secondary IDS0307
PubMed (PMID)32929540
Collaborator(s)National Cancer Institute (NCI)
North Central Cancer Treatment Group
Eastern Cooperative Oncology Group
NSABP Foundation Inc
Cancer and Leukemia Group B
NCIC Clinical Trials Group
Region(s)NA
Age RangeMinimum Age: 18 Years
Maximum Age: N/A
Files: NCT00127205-D1
Data DictionaryNCT00127205-D1-Data-Dictionary_1.pdf
DATANCT00127205-D1-Dataset_2.csv
OTHERREADME.pdf
Files: NCT00127205-D2
Data DictionaryNCT00127205-D2-Data-Dictionary_1.pdf
DATANCT00127205-D2-Dataset.csv
OTHERREADME.pdf
© 2021 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use